Literature DB >> 26397940

Adherens junctions associated protein 1 serves as a predictor of recurrence of squamous cell carcinoma of the esophagus.

Haruyoshi Tanaka1, Mitsuro Kanda1, Masahiko Koike1, Naoki Iwata1, Dai Shimizu1, Kazuhiro Ezaka1, Satoshi Sueoka1, Yuri Tanaka1, Hideki Takami1, Ryoji Hashimoto1, Chie Tanaka1, Suguru Yamada1, Tsutomu Fujii1, Goro Nakayama1, Hiroyuki Sugimoto1, Michitaka Fujiwara1, Yasuhiro Kodera1.   

Abstract

Esophageal squamous cell carcinoma (ESCC), the most common esophageal cancer in East Asia, is among the six cancers with the highest fatality rates worldwide. Unfortunately, multidisciplinary treatment strategies have not achieved satisfactory outcomes. Therefore, novel insights into the molecular biology of ESCC are required to improve treatment. The gene encoding the transmembrane adherens junctions-associated protein-1 (AJAP1) expressed by epithelial cells resides in chromosome 1p36, which is frequently lost or epigenetically silenced in several malignancies. Here, we investigated the expression levels and regulatory mechanism of AJAP1 transcription. We determined the levels of AJAP1 mRNA and the genes encoding potentially interacting proteins expressed by ESCC cell lines, as well as the chromosomal copy number of AJAP1 and the methylation status of its promoter region. AJAP1 mRNA levels of 78 pairs of surgically resected specimens were determined to evaluate the association of AJAP1 expression and clinicopathological factors. Nine ESCC cell lines differentially expressed AJAP1 mRNA, and demethylation of hypermethylated AJAP1 genomic DNA reactivated AJAP1 mRNA expression. The copy number of sequences upstream or downstream of the AJAP1 transcriptional start site was not detectably altered. AJAP1 mRNA levels correlated inversely with those of ezrin (EZR) and were significantly lower in ESCC tissues compared with adjacent normal tissues. AJAP1 mRNA levels decreased gradually with increasing tumor stage. Patients with downregulated AJAP1 transcription were more likely to experience shorter overall and disease-free survival. Multivariate analysis of disease-free survival identified downregulated AJAP1 transcription as an independent prognostic factor. These results suggest that in ESCC, AJAP1 acts as a putative tumor suppressor and that AJAP1 transcription is regulated by promoter hypermethylation. These findings indicate that downregulated AJAP1 transcription may serve as a novel tumor biomarker to predict recurrence of ESCC after esophagectomy.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26397940     DOI: 10.3892/ijo.2015.3167

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  16 in total

1.  Identification of NCCRP1 as an epigenetically regulated tumor suppressor and biomarker for malignant phenotypes of squamous cell carcinoma of the esophagus.

Authors:  Takashi Miwa; Mitsuro Kanda; Masahiko Koike; Naoki Iwata; Haruyoshi Tanaka; Shinichi Umeda; Chie Tanaka; Daisuke Kobayashi; Masamichi Hayashi; Suguru Yamada; Tsutomu Fujii; Michitaka Fujiwara; Yasuhiro Kodera
Journal:  Oncol Lett       Date:  2017-08-14       Impact factor: 2.967

2.  Identifying the role of transient receptor potential channels (TRPs) in kidney renal clear cell carcinoma and their potential therapeutic significances using genomic and transcriptome analyses.

Authors:  Jie Ren; Qihang Yuan; Jifeng Liu; Lei Zhong; Hanshuo Li; Guangzhen Wu; Feng Chen; Qizhen Tang
Journal:  BMC Med Genomics       Date:  2022-07-13       Impact factor: 3.622

Review 3.  Molecular mechanisms of peritoneal dissemination in gastric cancer.

Authors:  Mitsuro Kanda; Yasuhiro Kodera
Journal:  World J Gastroenterol       Date:  2016-08-14       Impact factor: 5.742

4.  Genome-wide association studies and epigenome-wide association studies go together in cancer control.

Authors:  Mukesh Verma
Journal:  Future Oncol       Date:  2016-04-15       Impact factor: 3.404

5.  Endogenous AJAP1 associates with the cytoskeleton and attenuates angiogenesis in endothelial cells.

Authors:  Katharina Hötte; Isabell Smyrek; Anna Starzinski-Powitz; Ernst H K Stelzer
Journal:  Biol Open       Date:  2017-06-15       Impact factor: 2.422

6.  GPR155 Serves as a Predictive Biomarker for Hematogenous Metastasis in Patients with Gastric Cancer.

Authors:  Dai Shimizu; Mitsuro Kanda; Haruyoshi Tanaka; Daisuke Kobayashi; Chie Tanaka; Masamichi Hayashi; Naoki Iwata; Yukiko Niwa; Hideki Takami; Suguru Yamada; Tsutomu Fujii; Goro Nakayama; Michitaka Fujiwara; Yasuhiro Kodera
Journal:  Sci Rep       Date:  2017-02-06       Impact factor: 4.379

7.  Identifying DNA methylation biomarkers for non-endoscopic detection of Barrett's esophagus.

Authors:  Helen R Moinova; Thomas LaFramboise; James D Lutterbaugh; Apoorva Krishna Chandar; John Dumot; Ashley Faulx; Wendy Brock; Omar De la Cruz Cabrera; Kishore Guda; Jill S Barnholtz-Sloan; Prasad G Iyer; Marcia I Canto; Jean S Wang; Nicholas J Shaheen; Prashanti N Thota; Joseph E Willis; Amitabh Chak; Sanford D Markowitz
Journal:  Sci Transl Med       Date:  2018-01-17       Impact factor: 19.319

8.  Epigenome-wide association study in hepatocellular carcinoma: Identification of stochastic epigenetic mutations through an innovative statistical approach.

Authors:  Davide Gentilini; Stefania Scala; Germano Gaudenzi; Paolo Garagnani; Miriam Capri; Matteo Cescon; Gian Luca Grazi; Maria Giulia Bacalini; Serena Pisoni; Alessandra Dicitore; Luisa Circelli; Sara Santagata; Francesco Izzo; Anna Maria Di Blasio; Luca Persani; Claudio Franceschi; Giovanni Vitale
Journal:  Oncotarget       Date:  2017-06-27

9.  Seven-CpG-based prognostic signature coupled with gene expression predicts survival of oral squamous cell carcinoma.

Authors:  David C Christiani; Sipeng Shen; Guanrong Wang; Qianwen Shi; Ruyang Zhang; Yang Zhao; Yongyue Wei; Feng Chen
Journal:  Clin Epigenetics       Date:  2017-08-24       Impact factor: 6.551

10.  High expression of cluster of differentiation 276 indicates poor prognosis in glioma.

Authors:  Linchen Li; Min Zhang; Dengna Zhu; Xinjun Wang
Journal:  Clin Med Insights Oncol       Date:  2021-07-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.